Strategic funding Strong multi-source funding and near-term debt and equity financing ahead of Phase III create a compelling window for BD partnerships and co-development discussions with potential big pharma or specialty biotechs seeking late-stage collaboration milestones.

Late-stage potential Lanifibranor holds FDA Breakthrough Therapy Designation and is in global Phase 3, signaling a high-priority asset with unmet need in MASH. This positions Inventiva as an attractive partner for licensing, co-development, or exclusive regional rights with milestone-driven deals.

Clinical momentum Recent investor and industry visibility through major conferences and debt/equity announcements indicate growing interest. Use this momentum to schedule targeted outreach to companies focused on metabolic liver diseases, fibrosis, and cardiometabolic risk.

Scale-ready Company size (51-200 employees) and ongoing Phase 3 readiness suggest a lean, agile partner profile for collaboration, enabling scalable manufacturing, regulatory strategy support, and rapid alignment on trial-readout timelines with potential partners.

Global reach Global trial footprint and listed exposure imply readiness for international commercialization conversations, including regional licensing, distribution partnerships, and access programs to expand lanifibranor adoption beyond core markets.